ImmunityBio Inc (IBRX) concluded trading on Thursday at a closing price of $2.60, with 6.43 million shares of worth about $16.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.02% during that period and on May 29, 2025 the price saw a gain of about 5.69%. Currently the company’s common shares owned by public are about 853.39M shares, out of which, 91.82M shares are available for trading.
Stock saw a price change of -1.89% in past 5 days and over the past one month there was a price change of 4.42%. Year-to-date (YTD), IBRX shares are showing a performance of 1.56% which decreased to -60.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.83 but also hit the highest price of $7.63 during that period. The average intraday trading volume for ImmunityBio Inc shares is 7.84 million. The stock is currently trading 5.67% above its 20-day simple moving average (SMA20), while that difference is down -1.06% for SMA50 and it goes to -24.23% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 853.39M outstanding shares and institutions hold larger chunk of about 9.08% of that.
The stock has a current market capitalization of $2.29B and its 3Y-monthly beta is at -0.00. It has posted earnings per share of -$0.58 in the same period. It has Quick Ratio of 2.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 4.81% while standing at 7.22% over the month.
Stock’s fiscal year EPS is expected to rise by 23.85% while it is estimated to increase by 37.73% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 20, 2025 offering an Overweight rating for the stock and assigned a target price of $5 to it. Coverage by H.C. Wainwright stated ImmunityBio Inc (IBRX) stock as a Buy in their note to investors on March 06, 2025, suggesting a price target of $8 for the stock. On January 10, 2025, BTIG Research Initiated their recommendations, while on May 12, 2023, Piper Sandler Downgrade their ratings for the stock with a price target of $4. Stock get a Buy rating from Jefferies on August 03, 2022.
